EXTON, PA — Melior Pharmaceuticals announced that it has received clearance of its Investigational New Drug (IND) application for the clinical development of its novel, first-in-class lyn kinase activator, tolimidone, for the treatment of COVID-19.
Pre-clinical studies in animal models related to COVID-19 demonstrate that tolimidone is a therapeutic expected to significantly mitigate the occurrence and severity of pulmonary symptoms in COVID-19 and other diseases associated with pulmonary complications that develop as a result of “cytokine storm” including sepsis.
As with all of Melior’s drug candidates, this is a repositioned drug that has been shown to be safe and well-tolerated in previous clinical studies.
The planned Phase 2 study is intended to recruit 236 subjects who were recently diagnosed with COVID-19, have early symptoms, but are not hospitalized. Tolimidone will be taken as an orally administered pill once a day.
“We are very proud of the fact that in less than a year since COVID-19 was declared a global pandemic, we developed and tested hypotheses, discovered a therapeutic candidate, and have progressed today with an active IND for what is a truly innovative therapy,” said Andrew Reaume, CEO of Melior Pharmaceuticals. “Moreover, tolimidone holds promise as a novel form of therapy for a number of other pulmonary related diseases beyond COVID-19.”
Thanks for visiting! Looking for some Chester County pride? We got you covered! Shop our MyChesCo store and show your love for Chester County, Pennsylvania. We got shirts, hats, and more – all with a unique ChesCo flair. Plus, proceeds from each purchase helps support our mission of bringing reliable information and resources to the people of Chester County.